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Nanomedicine, an emerging new field created by the fusion of nanotechnology and
medicine, is one of the most promising pathways for the development of effective
targeted therapies with oncology being the earlier and the most notable beneficiary
to date. Indeed, drug-loaded nanoparticles provide an ideal solution to overcome the
low selectivity of the anticancer drugs towards the cancer cells in regards to normal
cells and the induced severe side-effects, thanks to their passive and/or active
targeting to cancer tissues. Liposome-based systems encapsulating drugs are already
used in some cancer therapies (e.g. Myocet, Daunoxome, Doxil). But liposomes have
some important drawbacks: they have a low capacity to encapsulate lipophilic drugs
(even though it exists), they are manufactured through processes involving organic
solvents, and they are leaky, unstable in biological fluids and more generally in
aqueous solutions for being commercialized as such. We have developed new nano-
cargos, the lipid nanocapsules, with sizes below the endothelium fenestration (phi
inférieur à 100 nm), that solve these disadvantages. They are prepared according to a
solvent-free process and they are stable for at least one year in suspension ready for
injection, which should reduce considerably the cost and convenience for treatment.
Moreover, these new nano-cargos have the ability to encapsulate efficiently lipophilic
drugs, offering a pharmaceutical solution for their intravenous administration. The
lipid nanocapsules (LNCs) have been prepared according to an original method based
on a phase-inversion temperature process recently developed and patented. Their
structure is a hybrid between polymeric nanocapsules and liposomes because of their
oily core which is surrounded by a tensioactive rigid membrane. They have a
lipoprotein-like structure. Their size can be adjusted below 100 nm with a narrow
distribution. Importantly, these properties confer great stability to the structure
(physical stability >18 months). Blank or drug-loaded LNCs can be prepared, with or
without PEG (polyethyleneglycol)ylation that is a key parameter that affects the
vascular residence time of the nano-cargos. Other hydrophilic tails can also be
grafted. Different anticancer drugs (paclitaxel, docetaxel, etoposide,
hydroxytamoxifen, doxorubicin, etc.) have been encapsulated. They all are released
according to a sustained pattern. Preclinical studies on cell cultures and animal
models of tumors have been performed, showing promising results.
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